Tag: obesity
-
Genes, smoking and obesity raise pneumonia risk, especially for older adults
New findings highlight multiple risk factors for pneumonia in older adults Researchers from the University of Oulu have identified a combo of factors that increase the likelihood of developing pneumonia, a serious lung infection that is a leading cause of illness and hospitalization among older adults. The study emphasizes that genetic predisposition, when combined with…
-
Genes, Smoking and Obesity Raise Pneumonia Risk, Especially for Older Adults
Genetic and Lifestyle Factors Converge to Elevate Pneumonia Risk Pneumonia remains a leading cause of illness and mortality among older adults. A new study from researchers at the University of Oulu sheds light on how inherited genetic factors interact with lifestyle risks to influence an individual’s susceptibility to pneumonia. While genetics can set a baseline…
-
Genes, Smoking and Obesity Increase Pneumonia Risk in Older Adults
Overview Pneumonia remains a major health threat for older adults, but new research from the University of Oulu sheds light on why some individuals are more vulnerable than others. The study identifies specific inherited genes that heighten susceptibility to pneumonia and highlights how lifestyle factors—namely smoking and higher body mass—can amplify this risk. While genetics…
-
Why GLP-1 Drugs Aren’t a One-Size-Fits-All for Obesity—and How Personalized Care Could Change the Future
GLP-1 drugs aren’t a universal solution for obesity For many people, GLP-1 receptor agonists have offered meaningful weight loss and better appetite control. But in clinical practice, a sizable number of patients experience limited benefit or unpleasant side effects, raising questions about the one-size-fits-all approach to obesity pharmacotherapy. As scientists and clinicians look ahead, the…
-
GLP-1 Drugs Aren’t One-Size-Fits-All: Toward Personalized Obesity Care
GLP-1 Drugs Aren’t One-Size-Fits-All Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed obesity treatment in recent years. They’ve helped many people reduce weight, improve metabolic markers, and support healthier lifestyles. Yet a growing body of evidence shows that GLP-1 medications don’t work equally well for every patient. Some people lose substantial weight, while others experience modest…
-
Personalized Obesity Care: GLP-1 Drugs and the Future
Introduction: GLP-1 drugs offer hope but aren’t a universal fix GLP-1 receptor agonists have become a cornerstone for treating obesity in many patients, helping to curb appetite and promote weight loss. Yet doctors and researchers are increasingly aware that these medications don’t work the same for everyone. As medical science dives deeper into why some…
-
Heart Failure Prevalence in US Adults Surges 43% Since 1988
Overview: Heart Failure Prevalence Rises in US Adults A new analysis based on data tracked over several decades shows that the crude prevalence of heart failure (HF) among United States adults increased from 2.1% in 1988 to 3.0% in 2023. Reported in the Journal of the American College of Cardiology, the study highlights a notable…
-
How Weight Loss Resets Fat Tissue at the Cellular Level
Introduction: Why fat tissue health matters Obesity is not just about extra weight; it alters the biology of fat tissue (adipose tissue) in ways that raise the risk of metabolic diseases like type 2 diabetes and cardiovascular disease. Chronic low-grade inflammation, immune cell changes, and altered fat cell signaling contribute to insulin resistance and dysregulated…
-
Wegovy subsidised in Australia: equity drive behind health minister’s decision
Australia moves to subsidise Wegovy amid equity concerns In a landmark shift for Australian healthcare, the federal government announced that Wegovy, the popular weight-loss medication, will be subsidised. The decision, framed by health officials as an equity measure, aims to improve access to a treatment that has offered meaningful results for many with obesity and…
-
Wegovy Subsidised in Australia: Equity in Weight Loss
Australia moves to subsidise Wegovy in a bid for equitable weight loss treatment In a landmark policy shift, the Australian government announced that the weight loss drug Wegovy will be subsidised. The decision aims to improve access to a high-efficacy treatment for obesity, a condition that affects millions and carries significant health risks if left…